ES2912455T3 - Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico - Google Patents

Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico Download PDF

Info

Publication number: ES2912455T3
Authority: ES; Spain
Prior art keywords: fviii; amino acids; amino acid; peptide; acid sequence
Prior art date: 2010-10-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES17167928T

Other languages

English (en)

Spanish (es)

Inventor

Katharina Nora Steinitz

Van Helden Paula Maria Wilhelmina

Birgit Maria Reipert

Hans-Peter Schwarz

Hartmut Ehrlich

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-27

Filing date

2011-10-27

Publication date

2022-05-26

2011-10-27 Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd

2022-05-26 Application granted granted Critical

2022-05-26 Publication of ES2912455T3 publication Critical patent/ES2912455T3/es

Status Active legal-status Critical Current

2031-10-27 Anticipated expiration legal-status Critical

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 452
102000004196 processed proteins & peptides Human genes 0.000 title claims description 140
230000006058 immune tolerance Effects 0.000 title claims description 34
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 title claims description 25
102100026735 Coagulation factor VIII Human genes 0.000 title claims description 11
230000006698 induction Effects 0.000 title description 6
150000001413 amino acids Chemical class 0.000 claims abstract description 792
125000003275 alpha amino acid group Chemical group 0.000 claims abstract 14
238000000034 method Methods 0.000 claims description 151
210000001744 T-lymphocyte Anatomy 0.000 claims description 72
239000000203 mixture Substances 0.000 claims description 39
229920001184 polypeptide Polymers 0.000 claims description 25
102000043131 MHC class II family Human genes 0.000 claims description 20
108091054438 MHC class II family Proteins 0.000 claims description 20
238000004113 cell culture Methods 0.000 claims description 13
230000001939 inductive effect Effects 0.000 claims description 12
210000004408 hybridoma Anatomy 0.000 claims description 10
108091033319 polynucleotide Proteins 0.000 claims description 6
102000040430 polynucleotide Human genes 0.000 claims description 6
239000002157 polynucleotide Substances 0.000 claims description 6
238000000684 flow cytometry Methods 0.000 claims description 5
235000001014 amino acid Nutrition 0.000 description 439
229940024606 amino acid Drugs 0.000 description 439
108010054218 Factor VIII Proteins 0.000 description 429
102000001690 Factor VIII Human genes 0.000 description 428
229960000301 factor viii Drugs 0.000 description 387
210000004027 cell Anatomy 0.000 description 49
239000008194 pharmaceutical composition Substances 0.000 description 29
230000028993 immune response Effects 0.000 description 26
239000001963 growth medium Substances 0.000 description 17
238000009256 replacement therapy Methods 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 16
102000004169 proteins and genes Human genes 0.000 description 16
239000003153 chemical reaction reagent Substances 0.000 description 15
150000007523 nucleic acids Chemical class 0.000 description 15
208000009292 Hemophilia A Diseases 0.000 description 14
102000057593 human F8 Human genes 0.000 description 14
235000018102 proteins Nutrition 0.000 description 14
238000011502 immune monitoring Methods 0.000 description 13
230000014509 gene expression Effects 0.000 description 12
239000013598 vector Substances 0.000 description 12
239000000032 diagnostic agent Substances 0.000 description 11
229940039227 diagnostic agent Drugs 0.000 description 11
108020004707 nucleic acids Proteins 0.000 description 11
102000039446 nucleic acids Human genes 0.000 description 11
239000000523 sample Substances 0.000 description 11
238000011282 treatment Methods 0.000 description 11
-1 y-carboxyglutamate Chemical compound 0.000 description 11
239000000047 product Substances 0.000 description 10
201000003542 Factor VIII deficiency Diseases 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
239000002609 medium Substances 0.000 description 9
238000009093 first-line therapy Methods 0.000 description 8
108020004705 Codon Proteins 0.000 description 7
102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 7
108010039343 HLA-DRB1 Chains Proteins 0.000 description 7
208000031220 Hemophilia Diseases 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
210000003719 b-lymphocyte Anatomy 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
241000699670 Mus sp. Species 0.000 description 6
230000027455 binding Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000003814 drug Substances 0.000 description 6
238000004108 freeze drying Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000002265 prevention Effects 0.000 description 6
230000009467 reduction Effects 0.000 description 6
210000004989 spleen cell Anatomy 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
108010002350 Interleukin-2 Proteins 0.000 description 5
235000004279 alanine Nutrition 0.000 description 5
239000012472 biological sample Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000012544 monitoring process Methods 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000000126 substance Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
208000032843 Hemorrhage Diseases 0.000 description 4
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 4
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
208000034158 bleeding Diseases 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000007859 condensation product Substances 0.000 description 4
238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
230000004927 fusion Effects 0.000 description 4
102000054766 genetic haplotypes Human genes 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
229930182817 methionine Natural products 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000001514 detection method Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000007791 liquid phase Substances 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
239000002028 Biomass Substances 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 2
101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 2
101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 2
101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
108091008874 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
208000013633 acquired hemophilia Diseases 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
239000007640 basal medium Substances 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000004067 bulking agent Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
230000009465 prokaryotic expression Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
238000007860 single-cell PCR Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000008227 sterile water for injection Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
102100036826 Aldehyde oxidase Human genes 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
108091008875 B cell receptors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
108700031361 Brachyury Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
101150094690 GAL1 gene Proteins 0.000 description 1
102100028501 Galanin peptides Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108010051539 HLA-DR2 Antigen Proteins 0.000 description 1
108010091963 HLA-DRB1*15:01 antigen Proteins 0.000 description 1
101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
108700005092 MHC Class II Genes Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101710141347 Major envelope glycoprotein Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229940031675 advate Drugs 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
235000021120 animal protein Nutrition 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000005081 chemiluminescent agent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012537 formulation buffer Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
238000012007 large scale cell culture Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000012931 lyophilized formulation Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
101150079601 recA gene Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
235000021119 whey protein Nutrition 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Virology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)

ES17167928T 2010-10-27 2011-10-27 Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico Active ES2912455T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US40740210P	2010-10-27	2010-10-27
US201161467894P	2011-03-25	2011-03-25
US201161502476P	2011-06-29	2011-06-29

Publications (1)

Publication Number	Publication Date
ES2912455T3 true ES2912455T3 (es)	2022-05-26

Family

ID=45349271

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES11796846.1T Active ES2639039T3 (es)	2010-10-27	2011-10-27	Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico
ES17167928T Active ES2912455T3 (es)	2010-10-27	2011-10-27	Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
ES11796846.1T Active ES2639039T3 (es)	2010-10-27	2011-10-27	Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico

Country Status (20)

Country	Link
US (3)	US8969524B2 (2)
EP (2)	EP2632479B1 (2)
JP (2)	JP6122780B2 (2)
KR (2)	KR102040867B1 (2)
CN (2)	CN103298482B (2)
AR (1)	AR083586A1 (2)
AU (2)	AU2011319747C1 (2)
BR (1)	BR112013010362A2 (2)
CA (1)	CA2815239C (2)
DK (1)	DK2632479T3 (2)
EA (1)	EA034494B1 (2)
ES (2)	ES2639039T3 (2)
HK (1)	HK1215442A1 (2)
MX (1)	MX347805B (2)
NZ (2)	NZ609474A (2)
PL (2)	PL2632479T3 (2)
PT (1)	PT2632479T (2)
SG (2)	SG10201600656WA (2)
TW (3)	TWI580430B (2)
WO (1)	WO2012058480A1 (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100256062A1 (en)	2004-12-06	2010-10-07	Howard Tommy E	Allelic Variants of Human Factor VIII
EA036483B1 (ru) *	2012-11-12	2020-11-16	Эпитоп Интернэшнл Нв	Пептиды, способные индуцировать толерантность к рекомбинантному fviii, содержащая их композиция, их применение и способ лечения гемофилии
EP2928303A4 (en)	2012-12-07	2016-07-13	Haplomics Inc	FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
EP2968499A4 (en) *	2013-03-15	2016-11-30	Haplomics Inc	COMPOSITIONS AND METHODS FOR THE IMMUNO-TOLERANCE INDUCTION FOR FACTOR VIII SPATIAL THERAPIES IN PERSONS WITH HEMOPHILIA A
WO2015192101A1 (en) *	2014-06-12	2015-12-17	University Of Hawaii	Uses of humanized cobra venom factor for reducing or preventing immunogenicity
BR112017013981A2 (pt) *	2015-01-26	2018-01-02	Cellectis	receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
CA3020346A1 (en)	2016-04-15	2017-10-19	Baxalta Incorporated	Method and apparatus for providing a pharmacokinetic drug dosing regimen
US10896749B2 (en)	2017-01-27	2021-01-19	Shire Human Genetic Therapies, Inc.	Drug monitoring tool

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003087161A1 (en) *	2002-04-18	2003-10-23	Merck Patent Gmbh	Modified factor viii
US7485314B2 (en) *	2002-05-06	2009-02-03	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Induction of antigen specific immunologic tolerance
US20060141528A1 (en) *	2004-05-21	2006-06-29	Aebersold Rudolf H	Compositions and methods for quantification of serum glycoproteins
US20060094104A1 (en)	2004-10-29	2006-05-04	Leopold Grillberger	Animal protein-free media for cultivation of cells
ES2474573T3 (es)	2006-01-04	2014-07-09	Baxter International Inc	Medio de cultivo celular sin oligop�ptidos
GB0723712D0 (en) *	2007-12-04	2008-01-16	Apitope Technology Bristol Ltd	Peptides
US7673687B2 (en)	2007-12-05	2010-03-09	Halliburton Energy Services, Inc.	Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de)	2007-12-07	2008-02-28	Dittmann, Ludwig	Vorrichtung zur Raumbeduftung
GB0801513D0 (en) *	2008-01-28	2008-03-05	Circassia Ltd	Peptides from factor VIII
WO2009099991A2 (en)	2008-01-31	2009-08-13	The Brigham And Women's Hospital, Inc.	Treatment of cancer
MX339060B (es)	2008-11-07	2016-05-09	Baxter Int	Formulaciones del factor viii.

2011
- 2011-10-27 EP EP11796846.1A patent/EP2632479B1/en active Active
- 2011-10-27 WO PCT/US2011/058165 patent/WO2012058480A1/en not_active Ceased
- 2011-10-27 ES ES11796846.1T patent/ES2639039T3/es active Active
- 2011-10-27 AU AU2011319747A patent/AU2011319747C1/en active Active
- 2011-10-27 ES ES17167928T patent/ES2912455T3/es active Active
- 2011-10-27 MX MX2013004753A patent/MX347805B/es active IP Right Grant
- 2011-10-27 SG SG10201600656WA patent/SG10201600656WA/en unknown
- 2011-10-27 BR BR112013010362A patent/BR112013010362A2/pt not_active Application Discontinuation
- 2011-10-27 PL PL11796846T patent/PL2632479T3/pl unknown
- 2011-10-27 KR KR1020137013231A patent/KR102040867B1/ko active Active
- 2011-10-27 EA EA201390617A patent/EA034494B1/ru not_active IP Right Cessation
- 2011-10-27 JP JP2013536845A patent/JP6122780B2/ja not_active Expired - Fee Related
- 2011-10-27 TW TW100139078A patent/TWI580430B/zh not_active IP Right Cessation
- 2011-10-27 KR KR1020197032106A patent/KR102222864B1/ko not_active Expired - Fee Related
- 2011-10-27 US US13/283,452 patent/US8969524B2/en active Active
- 2011-10-27 PT PT117968461T patent/PT2632479T/pt unknown
- 2011-10-27 CN CN201180063117.9A patent/CN103298482B/zh active Active
- 2011-10-27 TW TW105138248A patent/TW201708251A/zh unknown
- 2011-10-27 CN CN201510431485.4A patent/CN104926947A/zh active Pending
- 2011-10-27 SG SG2013028733A patent/SG189914A1/en unknown
- 2011-10-27 NZ NZ609474A patent/NZ609474A/en unknown
- 2011-10-27 EP EP17167928.5A patent/EP3260132B1/en active Active
- 2011-10-27 NZ NZ703514A patent/NZ703514A/en unknown
- 2011-10-27 PL PL17167928.5T patent/PL3260132T3/pl unknown
- 2011-10-27 CA CA2815239A patent/CA2815239C/en active Active
- 2011-10-27 TW TW106113613A patent/TW201730205A/zh unknown
- 2011-10-27 DK DK11796846.1T patent/DK2632479T3/en active
- 2011-10-28 AR ARP110103988A patent/AR083586A1/es not_active Application Discontinuation
2015
- 2015-01-23 US US14/604,622 patent/US9512198B2/en active Active
2016
- 2016-03-22 HK HK16103339.6A patent/HK1215442A1/zh unknown
- 2016-04-06 AU AU2016202155A patent/AU2016202155B2/en active Active
- 2016-11-02 US US15/341,936 patent/US20170267743A1/en not_active Abandoned
- 2016-11-29 JP JP2016230723A patent/JP2017095463A/ja active Pending

Also Published As

Publication number	Publication date
BR112013010362A2 (pt)	2016-08-02
NZ609474A (en)	2015-06-26
MX347805B (es)	2017-05-15
DK2632479T3 (en)	2017-08-07
US8969524B2 (en)	2015-03-03
AR083586A1 (es)	2013-03-06
TW201231065A (en)	2012-08-01
US20150203567A1 (en)	2015-07-23
KR102040867B1 (ko)	2019-11-07
US20120135019A1 (en)	2012-05-31
JP6122780B2 (ja)	2017-04-26
KR20130128404A (ko)	2013-11-26
CN104926947A (zh)	2015-09-23
AU2016202155A1 (en)	2016-04-28
JP2014505014A (ja)	2014-02-27
JP2017095463A (ja)	2017-06-01
WO2012058480A1 (en)	2012-05-03
TWI580430B (zh)	2017-05-01
AU2011319747B2 (en)	2016-01-07
PT2632479T (pt)	2017-07-24
PL2632479T3 (pl)	2017-09-29
US9512198B2 (en)	2016-12-06
KR102222864B1 (ko)	2021-03-04
EP2632479A1 (en)	2013-09-04
US20170267743A1 (en)	2017-09-21
EA201390617A1 (ru)	2013-10-30
AU2011319747C1 (en)	2016-07-14
EP3260132A1 (en)	2017-12-27
EP3260132B1 (en)	2022-02-09
TW201708251A (zh)	2017-03-01
HK1215442A1 (zh)	2016-08-26
SG10201600656WA (en)	2016-02-26
CA2815239C (en)	2019-02-26
ES2639039T3 (es)	2017-10-25
AU2016202155B2 (en)	2018-02-01
PL3260132T3 (pl)	2022-08-08
CA2815239A1 (en)	2012-05-03
EA034494B1 (ru)	2020-02-13
SG189914A1 (en)	2013-06-28
AU2011319747A1 (en)	2013-05-02
EP2632479B1 (en)	2017-06-14
KR20190126189A (ko)	2019-11-08
MX2013004753A (es)	2013-09-13
NZ703514A (en)	2017-02-24
CN103298482B (zh)	2015-08-19
TW201730205A (zh)	2017-09-01
CN103298482A (zh)	2013-09-11

Publication	Publication Date	Title
ES2912455T3 (es)	2022-05-26	Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico
AU2021201265A1 (en)	2021-03-18	XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
JP2019502360A (ja)	2019-01-31	Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
AU2020202110A1 (en)	2020-04-16	Target peptides for colorectal cancer therapy and diagnostics
HK1246211A1 (en)	2018-09-07	Fviii peptides for immune tolerance induction and immunodiagnostics
ES2751361T3 (es)	2020-03-31	Factor VIII de la coagulación con inmunogenicidad reducida
HK1246211B (en)	2022-07-22	Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954A (en)	2014-05-23	Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954B (en)	2018-04-13	Fviii peptides for immune tolerance induction and immunodiagnostics
EA043749B1 (ru)	2023-06-19	Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
US20250161357A1 (en)	2025-05-22	Human t cell receptor pairs reactive with hla-a*02:01 restricted human prostatic acid phosphatase (pap) epitopes